Expression of creb-binding protein and peroxisome proliferator-activated receptor gamma during formoterol or formoterol and corticosteroid therapy of chronic obstructive pulmonary disease

Journal of Physiology and Pharmacology

Volumn 59, Issue SUPPL. 6, 2008, Pages 303-309

  Holownia, A ^a   Mroz, R M ^a   Noparlik, J ^a   Chyczewska, E ^a   Braszko, J J ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

CBP; COPD therapy; CREB; Glucocorticoids; PPAR

Indexed keywords

8 ISOPROSTANE; BUDESONIDE; CORTICOSTEROID; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; FORMOTEROL; GLUCOCORTICOID RECEPTOR; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; 8 EPI PROSTAGLANDIN F2ALPHA; 8-EPI-PROSTAGLANDIN F2ALPHA; BRONCHODILATING AGENT; DRUG DERIVATIVE; ETHANOLAMINE DERIVATIVE; GLUCOCORTICOID; PROSTAGLANDIN F2 ALPHA;

ARTICLE; CELL DIFFERENTIATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DNA RESPONSIVE ELEMENT; ENZYME IMMUNOASSAY; HUMAN; LYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; TREATMENT DURATION; WESTERN BLOTTING; BIOSYNTHESIS; BLOOD; CYTOLOGY; DRUG COMBINATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FORCED EXPIRATORY VOLUME; GENETICS; OXIDATIVE STRESS; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPUTUM;

BLOTTING, WESTERN; BRONCHODILATOR AGENTS; CREB-BINDING PROTEIN; DINOPROST; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; ETHANOLAMINES; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HUMANS; OXIDATIVE STRESS; PPAR GAMMA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, GLUCOCORTICOID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPUTUM;

EID: 64549136219     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Adcock IM, Ito K. Glucocorticoid pathways in chronic obstructive pulmonary disease therapy. Proc Am Thorac Soc 2005; 2: 313-319.
2. Mroz RM, Holownia A, Chyczewska E et al. Cytoplasm-nuclear trafficking of CREB and CREB phosphorylation at Ser133 during therapy of chronic obstructive pulmonary disease. J Physiol Pharmacol 2007; 58 Suppl 5: 437-444.
3. Ito K, Getting SJ, Charron CE. Mode of glucocorticoid actions in airway disease. Scientific World Journal 2006; 28: 1750-1769.
4. Ito K, Charron CE, Adcock IM. Impact of protein acetylation in inflammatory lung diseases. Pharmacol Ther 2007; 116: 249-265.
5. Goulding NJ. The molecular complexity of glucocorticoid actions in inflammation - a four-ring cirrus. Curr Opin Pharmacol 2004; 4: 629-636.
6. Takahashi N, Kawada T, Yamamoto T et al. Overexpression and ribozyme-mediated targeting of transcriptional coactivators, CREB binding protein (CBP) and p300, revealed their indispensable roles in adipocyte differentiation through the regulation of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) J Biol Chem 2002; 277: 16906-19911.
7. Smoak KA, Cidlowski JA. Mechanisms of glucocorticoid receptor signaling during inflammation. Mech Ageing Dev 2004; 125: 697-706.
8. Mamessier E, Boniface S, Dupuy P, Reynaud-Gaubert M, Vervloet D, Magnan A. Study of cytokine gene expression in small cell samples: use in induced sputum. J Immunol Methods 2003; 280: 37-47.
9. Celli BR. Update on the Management of COPD. Chest 2008; 133: 1451-1462.
10. Adcock IM, Caramori G, Ito K. New insights into the molecular mechanisms of corticosteroids actions. Curr Drug Targets 2006; 7: 649-660.
11. Barnes PJ, Ito K, Adcock IM. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 2004; 363: 731-733.
12. Hirano T, Yamagata T, Gohda M et al. Inhibition of reactive nitrogen species production in COPD airways: comparison of inhaled corticosteroid and oral theophylline. Thorax 2006; 61: 761-766.
13. Bhavsar P, Ahmad T, Adcock IM. The role of histone deacetylases in asthma and allergic diseases J Allergy Clin Immunol 2008; 121: 580-584.
14. Jungmann RA, Wang XS, Milkowski DM, Short ML. Glucocorticoid induction of CRE-binding protein isoform mRNAs in rat C6 glioma cells. Nucleic Acids Res 1992; 20: 825-829.
15. Sands WA, Palmer TM. Regulating gene transcription in response to cyclic AMP elevation. Cell Signal 2008; 20: 460-466.
16. Smoak KA, Cidlowski JA. Mechanisms of glucocorticoid receptor signaling during inflammation. Mech Ageing Dev 2004; 125: 697-706.
17. Clark AR. Anti-inflammatory functions of glucocorticoid-induced genes. Mol Cell Endocrinol 2007; 275: 79-97.
18. McKay LI, Cidlowski JA. CBP (CREB Binding Protein) integrates NF-kappaB (nuclear factor- kappaB) and glucocorticoid receptor physical interactions and antagonism. Mol Endocrinol 2000; 14: 1222-1234.
19. McKay LI, Cidlowski JA. CBP (CREB binding protein) integrates NF-kappaB (nuclear factor- kappaB) and glucocorticoid receptor physical interactions and antagonism. Mol Endocrinol 2000; 14: 1222-1234.
20. Nie M, Corbett L, Knox AJ, Pang L. Differential regulation of chemokine expression by peroxisome proliferator-activated receptor gamma agonists: interactions with glucocorticoids and beta2-agonists. J Biol Chem 2005; 280: 2550-2561.
21. Bonofiglio D, Aquila S, Catalano S et al. Peroxisome proliferator-activated receptor-gamma activates p53 gene promoter binding to the nuclear factor-kappaB sequence in human MCF7 breast cancer cells. Mol Endocrinol 2006; 20: 3083-3092.
22. Wang P, Anderson PO, Chen S, Paulsson KM, Sjogren HO, Li S. Inhibition of the transcription factors AP-1 and NF-kappaB in CD4 T cells by peroxisome proliferator-activated receptor gamma ligands. Int Immunopharmacol 2001; 1: 803-812.
23. Wahli W. A gut feeling of the PXR, PPAR and NF-kappaB connection. J Intern Med 2008; 263: 613-619.